We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

125 hedge funds and large institutions have $905M invested in C4 Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more call options, than puts

Call options by funds: $13.1M | Put options by funds: $5.3M

47% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 32

26% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 23

5% more funds holding

Funds holding: 119 → 125 (+6)

2.76% more ownership

Funds ownership: 73.81% → 76.58% (+2.8%)

22% less capital invested

Capital invested by funds: $1.15B → $905M (-$249M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
125
Holders Change
+6
Holders Change %
+5.04%
% of All Funds
1.97%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
29
Increased
47
Reduced
32
Closed
23
Calls
$13.1M
Puts
$5.3M
Net Calls
+$7.83M
Net Calls Change
+$5.92M

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$49.5M
2
State Street
State Street
Massachusetts
+$15.5M
3
PVI
Pura Vida Investments
New York
+$14.5M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.2M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.1M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$44.4M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$32.1M
3
LCM
Laurion Capital Management
New York
-$18.7M
4
SCM
Soleus Capital Management
Connecticut
-$9.58M
5
Invesco
Invesco
Georgia
-$7.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
126
Laurion Capital Management
New York
– -$18.7M -581,028 Closed
Walleye Capital
127
Walleye Capital
New York
– -$2.63M -81,720 Closed
Voloridge Investment Management
128
Voloridge Investment Management
Florida
– -$1.96M -60,903 Closed
Bank of Montreal
129
Bank of Montreal
Ontario, Canada
– -$1.78M -54,100 Closed
Federated Hermes
130
Federated Hermes
Pennsylvania
– -$1.35M -41,897 Closed
GCM
131
Goldstream Capital Management
Hong Kong
– -$1.17M -36,193 Closed
Renaissance Technologies
132
Renaissance Technologies
New York
– -$1.01M -31,300 Closed
Jennison Associates
133
Jennison Associates
New York
– -$869K -27,001 Closed
D.E. Shaw & Co
134
D.E. Shaw & Co
New York
– -$829K -25,735 Closed
Tudor Investment Corp
135
Tudor Investment Corp
Connecticut
– -$685K -21,283 Closed
Vontobel Holding
136
Vontobel Holding
Switzerland
– -$644K -20,000 Closed
MAM
137
Martingale Asset Management
Massachusetts
– -$519K -16,109 Closed
ECM
138
EMC Capital Management
Texas
– -$342K -10,619 Closed
DACS
139
Dymon Asia Capital (Singapore)
Singapore
– -$266K -8,250 Closed
Handelsbanken Fonder
140
Handelsbanken Fonder
Sweden
– -$264K -8,200 Closed
SG Americas Securities
141
SG Americas Securities
New York
– -$230K -7,149 Closed
Principal Financial Group
142
Principal Financial Group
Iowa
– -$212K -6,570 Closed
QT
143
Quantbot Technologies
New York
– -$54K -1,700 Closed
MIFH
144
Migdal Insurance & Financial Holdings
Israel
– -$20K -605 Closed
CT
145
Cambridge Trust
Massachusetts
– -$3K -100 Closed
FFG
146
Ford Financial Group
California
– -$1 -50 Closed
C
147
Covestor
United Kingdom
– -$49 -2 -18%
FHA
148
First Horizon Advisors
Tennessee
– +$364 +15 New
2 3 4 5
6

CCCC Hedge Fund Activity: Q1 2022 in Review

125 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2022, worth a combined $905M — down 22% from $1.15B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CCCC positions and 23 closed out — a net gain of 6 holders — while 47 added to existing stakes and 32 trimmed.

The largest buyer was RTW Investments, adding an estimated $49.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $44.4M sold.

  • 125 institutional investors held C4 Therapeutics (CCCC) as of Q1 2022, up from 119 in Q4 2021.
  • Funds reported $905M of C4 Therapeutics stock for Q1 2022, down 22% quarter-over-quarter.
  • 29 funds opened new C4 Therapeutics positions in Q1 2022 and 23 closed out, a net change of +6 holders.
  • The largest C4 Therapeutics buyer in Q1 2022 was RTW Investments, an estimated $49.5M added.
  • The largest C4 Therapeutics seller in Q1 2022 was RA Capital Management, an estimated $44.4M sold.

Based on aggregated 13F filings for Q1 2022.